SceintifiC FOUNDER

Preet Chaudhary, MD, PhD is Professor of Medicine, Chief of the Jane Ann Nohl Division of Hematology and Center for the Study of Blood Diseases and the Ronald Bloom Family Chair in Lymphoma Research at the Keck School of Medicine of the University of Southern California (USC). He is also the Director of USC Blood and Marrow Transplant and Immune Effector Cell Therapy Programs.   

Dr. Chaudhary is a nationally recognized physician-scientist with research interests in several areas of cancer including Chimeric Antigen Receptor modified T cells (CAR-T), cancer drug resistance, biology of normal and leukemic hematopoietic stem cells, programmed cell death and novel therapies for leukemia, lymphoma, multiple myeloma and solid tumors.

Dr. Chaudhary obtained his medical degree from Delhi University and PhD from the University of Illinois at Chicago. Subsequently, he did residency training in Internal Medicine at the Northwestern University in Chicago and fellowship training in Hematology-Oncology at the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle. 

Dr. Chaudhary is an elected member of the American Society of Clinical Investigations and has been the recipient of fellowships and awards from March of Dimes Birth Defect Foundation, Damon Runyon-Walter Winchell Foundation, Leukemia Research Foundation, Leukemia Lymphoma Society, Multiple Myeloma Research Foundation, Howard Hughes Institutes and Western Regional Society. He has been listed in the “Top Doctors” of Pasadena and Los Angeles Magazines. Under Dr. Chaudhary's leadership, USC Blood and Marrow Transplant Program has consistently reported one of the highest 1 year survival among all adult allogeneic transplant programs in the nation and recently achieved a 90.3% survival, a historic first for any adult allogeneic program. Dr. Chaudhary has more than 150 patent applications pending world-wide in the area of cellular therapies. According to an article in PLOS ONE, he is the inventor of a patent application that is the highest cited anticancer patent in the world between 1993 and 2013.